{
    "clinical_study": {
        "@rank": "127873", 
        "arm_group": [
            {
                "arm_group_label": "A(Telmisartan/S-Amlodipine)", 
                "arm_group_type": "Experimental", 
                "description": "A(Telmisartan/S-Amlodipine)\n: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days"
            }, 
            {
                "arm_group_label": "B(Rosuvastatin)", 
                "arm_group_type": "Experimental", 
                "description": "B(Rosuvastatin)\n: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the drug-drug interaction of\n      CKD-346(Telmisartan/S-Amlodipine, Rosuvastatin)"
        }, 
        "brief_title": "CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypertension", 
            "Hyperlipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized, open-label, multiple-dose, two-arm, one-sequence \u00b7 crossover study to evaluate\n      the safety and pharmacokinetics after oral concurrent administration\n      telmisartan/s-amlodipine and rosuvastatin in healthy volunteers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Participant is a male or female between 20 and 45 years of age (inclusive) at the\n             pre-study (screening)\n\n          2. Participant who has a body weight that is >55kg(male) or >50kg(female) with ideal\n             body weight of 80-120% (ideal body weight) = {Height(cm) - 100} * 0.9\n\n          3. If female, must include more than one among the items\n\n               1. The menopause (there is no natural menses for at least 2 years)\n\n               2. Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or\n                  other methods of infertility condition)\n\n               3. The male partner infertility before screening (Demonstrated azoospermia after\n                  vasectomy)and if this man is the only partner of the female subject.\n\n               4. you are using one of the following contraceptive measure for 3 months before\n                  screening, and Necessarily you agree that used continuously contraceptive\n                  measure during the clinical trial and for 1 month after the final dosing\n                  investigational product.(But, should not use a device of contraception or oral\n                  contraceptive drug that containing a hormonal caused telmisartan, s-amlodipine,\n                  atorvastatin calcium drug interactions during the clinical trials)\n\n                    -  Abstinence.\n\n                    -  Physical interrupt method (such as a condom, contraceptive diaphoretic or\n                       cervical cap)\n\n               5. In case of women of childbearing age, the serum \u03b2-hCG pregnancy test is negative\n                  before taking the investigational product, and urine \u03b2-hCG test is negative\n                  before taking the investigational product.\n\n          4. If men has sexual life with women of childbearing age, Necessarily he agrees that use\n             condoms during clinical trials and do not sperm donation during clinical trials and\n             until one month after the final dosage of investigational products\n\n          5. Those who fully understand about this clinical trial after enough hearing, and then\n             decided to join the clinical trials by themselves and to comply with the precautions\n             written consent.\n\n        Exclusion Criteria:\n\n          1. The subject has a previous history of any clinically significant cardiovascular,\n             pulmonary, renal, endocrine, hematological, gastro-intestinal, neurological,\n             psychiatric, or malignancy.\n\n          2. Have a gastrointestinal disease history that can affect drug absorption (Crohn's\n             disease, ulcers, etc.) or surgery (except simple appendectomy or hernia surgery).\n\n          3. Hypersensitivity reaction to drug or clinically significant hypersensitivity reaction\n             in the history of Investigational drugs (telmisartan, s-amlodipine or rosuvastatin\n             calcium) or additives.\n\n          4. An impossible one who participates in clinical trial including screening\n             tests(medical history taking, V/S, physical examination, 12-lead ECG, blood & urine\n             laboratory test result)\n\n          5. Defined by the following laboratory parameters:\n\n               -  Hemoglobin < 13.0 g/dL(male), Hemoglobin < 12.0 g/dL(female)\n\n               -  AST, ALT> 1.25* upper limit of normal range\n\n               -  Total bilirubin > 1.5* upper limit of normal range\n\n               -  CPK > 1.5* upper limit of normal range\n\n               -  eGFR(using by MDRD method) < 60 mL/min/1.73m2\n\n          6. Sitting SBP > 150 mmHg or < 90 mmHg, Sitting DBP> 100 mmHg or < 50 mmHg , after\n             5minuts break.\n\n          7. Drug abuse or have a history of drug abuse showed a positive for urine drug test.\n\n          8. Female Participant is pregnant or lactating\n\n          9. A heavy caffeine consumer(caffeine>5cups/day), alcohol consumer(alcohol>210g/week),\n             or smoker(cigarette>10cigarettes/day)\n\n         10. Participation in any other study and have received any other investigational drug or\n             device within 90 days prior to study treatment.\n\n         11. Administration of drug metabolizing enzyme inducers or inhibitors such as barbitals\n             within 30 days prior to the first dosing.\n\n         12. Blood donation (1 unit or more) within 60 days prior to study treatment or plasma\n             donation within 30 days prior to study treatment.\n\n         13. Taking foods containing grapefruit within 7 days before the beginning of study\n             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days\n             before the beginning of study treatment)\n\n         14. Subject takes ethical drug or herbal medicine within 14days, OTC or vitamins within\n             7days before the beginning of study treatment.\n\n         15. An impossible one who participants in clinical trial by investigator's decision\n             including laboratory test result or another reason.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047175", 
            "org_study_id": "147DDI13019"
        }, 
        "intervention": [
            {
                "arm_group_label": "A(Telmisartan/S-Amlodipine)", 
                "description": "Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days", 
                "intervention_name": "Telmisartan/S-Amlodipine", 
                "intervention_type": "Drug", 
                "other_name": "Telminuvo tablet"
            }, 
            {
                "arm_group_label": "B(Rosuvastatin)", 
                "description": "Rosuvastatin 20mg 1T PO, QD for 5days", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Crestor tablet"
            }, 
            {
                "arm_group_label": "A(Telmisartan/S-Amlodipine)", 
                "description": "Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days", 
                "intervention_name": "Telmisartan/S-Amlodipine + Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Telminuvo tablet + Crestor tablet"
            }, 
            {
                "arm_group_label": "B(Rosuvastatin)", 
                "description": "Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days", 
                "intervention_name": "Telmisartan/S-Amlodipine + Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Telminuvo tablet + Crestor tablet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Telmisartan", 
                "Rosuvastatin", 
                "Benzoates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Gangnam-gu"
                }, 
                "name": "The catholic university of Korea, seoul ST.Mary's hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Multiple-dose, Two-arm, One-sequence \u2022 Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration Telmisartan/S-amlodipine and Rosuvastatin in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "The Catholic University of Korea", 
            "last_name": "Dong-seok Yim, professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUCt,ss of Telmisartan/S-Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h"
            }, 
            {
                "measure": "Cmax,ss of Telmisartan/S-Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h"
            }, 
            {
                "measure": "AUCt,ss of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h"
            }, 
            {
                "measure": "Cmax,ss of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tmax,ss of Telmisartan/S-Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h"
            }, 
            {
                "measure": "T1/2 of Telmisartan/S-Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h"
            }, 
            {
                "measure": "CL/F of Telmisartan/S-Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h"
            }, 
            {
                "measure": "Vd/F of Telmisartan/S-Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h"
            }, 
            {
                "measure": "R of Telmisartan/S-Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h"
            }, 
            {
                "measure": "Tmax,ss of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h"
            }, 
            {
                "measure": "T1/2 of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h"
            }, 
            {
                "measure": "CL/F of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h"
            }, 
            {
                "measure": "Vd/F of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h"
            }, 
            {
                "measure": "R of Rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}